Please note: The information displayed on this page might be outdated.
Quentis Therapeutics: Preclinical stage biotechnology company translating novel biology into new therapeutic approaches that target pathways associated with endoplasmic reticulum (ER) stress response. Lead program is a first-in-class IRE1α inhibitor designed to boost anti-tumor immunity in cancer. Quentis is pursuing therapies to address multiple ER stress pathway targets in the tumor micro-environment, as well as in other diseases where ER stress plays an important role. CEO - Michael Aberman (prev. Regeneron). Scientific founders - Laurie Glimcher, MD (President & CEO, Dana-Farber Cancer Institute), Juan Cubillos-Ruiz, PhD, and Sarah Bettigole, PhD. Quentis launched in February 2018 with a $48 million Series A financing.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Industry
Biotechnology
Listing
Private
Market Cap
Private
Website:
Address:
430 E 29th St, Suite 1005
New York, NY 10016
United States

Company Participants at Boston Private Company Showcase

  • Michael Aberman, CEO